Novartis appeals IP Australia decision invalidating MS drug patent
Intellectual Property June 3, 2019 4:11 pm By Cat Fredenburgh | Melbourne

Novartis has launched an appeal following a ruling by IP Australia that a proposed patent for an oral form of its top-selling multiple sclerosis drug […]

Subscribe for instant access to all Lawyerly content. Already a subscriber? Login here. Want to test drive Lawyerly? Contact us to take a free trial.